Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.77 |
| ▸ | LMNA | P02545 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | RAD52 | P43351 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.77 |
| ▸ | HTR1A | P08908 | 2/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.77 |
| ▸ | DRD2 | P14416 | 2/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclophenazine SCHEMBL29710907 | 1.00 | FPR2 (0.77) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Cyclophenazine SCHEMBL28173472 | 0.99 | LMNA (0.77) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Cyclophenazine SCHEMBL122920 | 0.99 | LMNA (0.77) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL31673764 | 0.92 | FPR2 (0.79) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20412084 | 0.92 | FPR2 (0.79) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20412094 | 0.91 | FPR2 (0.81) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL30703686 | 0.91 | FPR2 (0.81) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20412107 | 0.90 | FPR2 (0.79) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL31673755 | 0.90 | FPR2 (0.79) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL20427426 | 0.89 | FPR2 (0.72) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-11389453-B2 | Compositions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| WO-2003011255-A1 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| EP-1163011-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | Protarga Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| CN-1152941-A | Genes for synthesizing antipathogenic substances | CIBA GEIGY AG (CH) | 1997-06-25 | — | — | CN | disclosed |